Loading...
603079
XSHG
Market cap269mUSD
Nov 20, Last price  
9.51CNY
1D
-7.67%
1Q
-32.22%
IPO
-22.01%
Name

Zhejiang Shengda Bio-pharm Co Ltd

Chart & performance

D1W1MN
XSHG:603079 chart
P/E
28.92
P/S
2.13
EPS
0.33
Vol. 1Y
45.93%
Shs. 5Y
1.03%
Rev. 5Y
-0.53%
Div Yld LY
0.63%
Div Yld TTM
1.05%
Revenues
845m
+2.07%
449,254,400398,770,700380,897,100536,429,499482,147,680508,561,120492,709,860519,149,812867,314,752789,732,754738,019,049727,405,727827,401,959844,536,869
Net income
62m
+111.24%
52,360,20054,591,70043,785,10086,702,90060,935,62172,610,20744,544,42547,030,269197,438,34175,756,47631,484,429-54,062,93129,424,49362,155,711
CFO
139m
-6.08%
110,080,900105,279,80034,401,628148,071,83973,001,50495,334,03188,685,91258,553,623333,201,87574,460,43940,717,54664,421,472147,878,103138,884,551
Dividend
Jul 01, 20260.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Shengda Bio-Pharm Co., Ltd., based in Tiantai, China, is a global enterprise dedicated to the research, development, manufacturing, and distribution of a diverse range of food and animal feed additives. The company's comprehensive product portfolio includes essential vitamins like biotin and folic acid, biological preservation agents such as nisin and natamycin, and intermediate Active Pharmaceutical Ingredients (APIs). They also provide various natural solutions for food preservation.

Key people

Xiangxiao Xu
Finance Director · since 2022
Chao Liang
General Manager · since 2025
Bin Zhou
General Manager · since 2019
Chaoqun Hong
Deputy General Manager · since 2025
Han Pang
Deputy General Manager · since 2018
Xiao Xie
Deputy General Manager · since 2025
Wei Han
Secretary of the Board · since 2025
Director · since 2013
Bincheng Chu
Staff Elected Director · since 2025
Ai Hong
Chairman of the Board
Jianxin Xu
Deputy General Manager, Director · since 2022
Yonggang Zhu
Director · since 2022
Jing Zhu
Deputy General Manager, Director · since 2019
Yi-Xuan Zhu
Director · since 2025
Guohua Hu
Independent Director
Yongquan Li
Independent Director · since 2021
Independent Director · since 2025
IPO date
Aug 23, 2017
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT